Anavex Life Sciences Corp (AVXL)

[Jonjones325]

I'm glad to see them presenting both 9 and 12 month data. Building on the last presentation, these 2 data points should point to a more definitive trend. Neurontrix and cogstate data should also help confirm the findings.

Some suggest that the use of these companies along with Ariana are being used to find efficacy where it is not clearly seen. I think it's the exact opposite. It's to confirm what has been already found. So that they can reduce risk of failure.

Dr. Missling: The chief challenge is really to keep in mind that drug development has inherent risks, and we would like to address those in order to reduce those risks to the extent possible. So we try to always do everything to the best of our knowledge and ability to minimize clinical trial risks in particular. That is the most important task for us and for me.

The phase 3 will be designed with as little room for failure as possible. He has been saying this from the beginning. We are trying to fail now so we won't later.